Update: Update: Hypogonadotropic Hypogonadism in Type 2 Diabetes and Obesity (original) (raw)
1. Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P. 2004. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 89:5462–5468 [PubMed] [Google Scholar]
2. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. 2007. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30:911–917 [PubMed] [Google Scholar]
3. Rhoden EL, Ribeiro EP, Teloken C, Souto CA. 2005. Diabetes mellitus is associated with subnormal serum levels of free testosterone in men. BJU Int 96:867–870 [PubMed] [Google Scholar]
4. Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, Zajac JD, Jerums G. 2008. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 93:1834–1840 [PubMed] [Google Scholar]
5. Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Mansani R, Chiarini V, Giommi R, Forti G, Maggi M. 2006. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 18:190–197 [PubMed] [Google Scholar]
6. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. 2006. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91:1995–2010 [PubMed] [Google Scholar]
7. Chandel A, Dhindsa S, Topiwala S, Chaudhuri A, Dandona P. 2008. Testosterone concentration in young patients with diabetes. Diabetes Care 31:2013–2017 [PMC free article] [PubMed] [Google Scholar]
8. Dhindsa S, Furlanetto R, Vora M, Chaudhuri A, Ghanim H, Dandona P. 29 June 2011. Low estradiol concentrations in males with subnormal testosterone concentrations and type 2 diabetes. Diabetes Care 10.2337/dc11-0208 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Tomar R, Dhindsa S, Chaudhuri A, Mohanty P, Garg R, Dandona P. 2006. Contrasting testosterone concentrations in type 1 and type 2 diabetes. Diabetes Care 29:1120–1122 [PubMed] [Google Scholar]
10. Haffner SM. 2000. Sex hormones, obesity, fat distribution, type 2 diabetes and insulin resistance: epidemiological and clinical correlation. Int J Obes Relat Metab Disord 24(Suppl 2):S56–S58 [PubMed] [Google Scholar]
11. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Salonen R, Rauramaa R, Salonen JT. 2003. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 149:601–608 [PubMed] [Google Scholar]
12. Kapoor D, Channer KS, Jones TH. 2008. Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diab Vasc Dis Res 5:135–137 [PubMed] [Google Scholar]
13. Dhindsa S, Miller MG, McWhirter CL, Mager DE, Ghanim H, Chaudhuri A, Dandona P. 2010. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 33:1186–1192 [PMC free article] [PubMed] [Google Scholar]
14. Pitteloud N, Dwyer AA, DeCruz S, Lee H, Boepple PA, Crowley WF, Jr, Hayes FJ. 2008. The relative role of gonadal sex steroids and gonadotropin-releasing hormone pulse frequency in the regulation of follicle-stimulating hormone secretion in men. J Clin Endocrinol Metab 93:2686–2692 [PMC free article] [PubMed] [Google Scholar]
15. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC. 2010. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 95:1810–1818 [PubMed] [Google Scholar]
16. Brüning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Müller-Wieland D, Kahn CR. 2000. Role of brain insulin receptor in control of body weight and reproduction. Science 289:2122–2125 [PubMed] [Google Scholar]
17. Salvi R, Castillo E, Voirol MJ, Glauser M, Rey JP, Gaillard RC, Vollenweider P, Pralong FP. 2006. Gonadotropin-releasing hormone-expressing neurons immortalized conditionally are activated by insulin: implication of the mitogen-activated protein kinase pathway. Endocrinology 147:816–826 [PubMed] [Google Scholar]
18. Gamba M, Pralong FP. 2006. Control of GnRH neuronal activity by metabolic factors: the role of leptin and insulin. Mol Cell Endocrinol 254–255:133–139 [PubMed] [Google Scholar]
19. Watanobe H, Hayakawa Y. 2003. Hypothalamic interleukin-1β and tumor necrosis factor-α, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive axis in rats. Endocrinology 144:4868–4875 [PubMed] [Google Scholar]
20. Russell SH, Small CJ, Stanley SA, Franks S, Ghatei MA, Bloom SR. 2001. The in vitro role of tumour necrosis factor-α and interleukin-6 in the hypothalamic-pituitary gonadal axis. J Neuroendocrinol 13:296–301 [PubMed] [Google Scholar]
21. Bhatia V, Chaudhuri A, Tomar R, Dhindsa S, Ghanim H, Dandona P. 2006. Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care 29:2289–2294 [PubMed] [Google Scholar]
22. Vallerie SN, Furuhashi M, Fucho R, Hotamisligil GS. 2008. A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity. PLoS One 3:e3151. [PMC free article] [PubMed] [Google Scholar]
23. Dandona P, Aljada A, Bandyopadhyay A. 2004. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4–7 [PubMed] [Google Scholar]
24. Ghanim H, Aljada A, Daoud N, Deopurkar R, Chaudhuri A, Dandona P. 2007. Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects. Diabetologia 50:278–285 [PubMed] [Google Scholar]
25. Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ. 2005. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 90:2636–2641 [PubMed] [Google Scholar]
26. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. 2002. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 25:55–60 [PubMed] [Google Scholar]
27. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. 1996. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 143:889–897 [PubMed] [Google Scholar]
28. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. 2004. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036–1041 [PubMed] [Google Scholar]
29. Lakshman KM, Bhasin S, Araujo AB. 2010. Sex hormone-binding globulin as an independent predictor of incident type 2 diabetes mellitus in men. J Gerontol A Biol Sci Med Sci 65:503–509 [PMC free article] [PubMed] [Google Scholar]
30. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM, Liu S. 2009. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 361:1152–1163 [PMC free article] [PubMed] [Google Scholar]
31. Perry JR, Weedon MN, Langenberg C, Jackson AU, Lyssenko V, Sparsø T, Thorleifsson G, Grallert H, Ferrucci L, Maggio M, Paolisso G, Walker M, Palmer CN, Payne F, Young E, Herder C, Narisu N, Morken MA, Bonnycastle LL, Owen KR, Shields B, Knight B, Bennett A, Groves CJ, Ruokonen A, Jarvelin MR, Pearson E, Pascoe L, Ferrannini E, Bornstein SR, Stringham HM, Scott LJ, Kuusisto J, Nilsson P, Neptin M, Gjesing AP, Pisinger C, Lauritzen T, Sandbaek A, Sampson M, Zeggini E, Lindgren CM, Steinthorsdottir V, Thorsteinsdottir U, Hansen T, Schwarz P, Illig T, Laakso M, Stefansson K, Morris AD, Groop L, Pedersen O, Boehnke M, Barroso I, Wareham NJ, Hattersley AT, McCarthy MI, Frayling TM. 2010. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet 19:535–544 [PMC free article] [PubMed] [Google Scholar]
32. Behrend L, Vibe-Petersen J, Perrild H. 2005. Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. Int J Impot Res 17:264–269 [PubMed] [Google Scholar]
33. Laughlin GA, Barrett-Connor E, Bergstrom J. 2008. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93:68–75 [PMC free article] [PubMed] [Google Scholar]
34. Tivesten A, Vandenput L, Labrie F, Karlsson MK, Ljunggren O, Mellström D, Ohlsson C. 2009. Low serum testosterone and estradiol predict mortality in elderly men. J Clin Endocrinol Metab 94:2482–2488 [PubMed] [Google Scholar]
35. Yeap BB, Hyde Z, Almeida OP, Norman PE, Chubb SA, Jamrozik K, Flicker L, Hankey GJ. 2009. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab 94:2353–2359 [PubMed] [Google Scholar]
36. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. 2007. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116:2694–2701 [PubMed] [Google Scholar]
37. Vikan T, Johnsen SH, Schirmer H, Njølstad I, Svartberg J. 2009. Endogenous testosterone and the prospective association with carotid atherosclerosis in men: the Tromso study. Eur J Epidemiol 24:289–295 [PubMed] [Google Scholar]
38. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. 2006. Low serum testosterone and mortality in male veterans. Arch Intern Med 166:1660–1665 [PubMed] [Google Scholar]
39. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. 2007. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 167:1252–1260 [PubMed] [Google Scholar]
40. Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. 2005. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation 112:332–340 [PubMed] [Google Scholar]
41. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. 2010. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96:1821–1825 [PubMed] [Google Scholar]
42. Ponikowska B, Jankowska EA, Maj J, Wegrzynowska-Teodorczyk K, Biel B, Reczuch K, Borodulin-Nadzieja L, Banasiak W, Ponikowski P. 2010. Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. Int J Cardiol 143:343–348 [PubMed] [Google Scholar]
43. Dhindsa S, Bhatia V, Dhindsa G, Chaudhuri A, Gollapudi GM, Dandona P. 2007. The effects of hypogonadism on body composition and bone mineral density in type 2 diabetic patients. Diabetes Care 30:1860–1861 [PubMed] [Google Scholar]
44. Traish AM, Saad F, Feeley RJ, Guay A. 2009. The dark side of testosterone deficiency. III. Cardiovascular disease. J Androl 30:477–494 [PubMed] [Google Scholar]
45. Dandona P, Dhindsa S, Chaudhuri A, Bhatia V, Topiwala S, Mohanty P. 2008. Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr Mol Med 8:816–828 [PubMed] [Google Scholar]
46. Grossmann M, Panagiotopolous S, Sharpe K, MacIsaac RJ, Clarke S, Zajac JD, Jerums G, Thomas MC. 2009. Low testosterone and anaemia in men with type 2 diabetes. Clin Endocrinol (Oxf) 70:547–553 [PubMed] [Google Scholar]
47. Shahidi NT. 1973. Androgens and erythropoiesis. N Engl J Med 289:72–80 [PubMed] [Google Scholar]
48. Orwoll ES, Klein RF. 1995. Osteoporosis in men. Endocr Rev 16:87–116 [PubMed] [Google Scholar]
49. Jackson JA, Riggs MW, Spiekerman AM. 1992. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 304:4–8 [PubMed] [Google Scholar]
50. Benito M, Gomberg B, Wehrli FW, Weening RH, Zemel B, Wright AC, Song HK, Cucchiara A, Snyder PJ. 2003. Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 88:1497–1502 [PubMed] [Google Scholar]
51. Khosla S, Melton LJ, 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. 1998. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266–2274 [PubMed] [Google Scholar]
52. Mellström D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M, Mallmin H, Holmberg A, Redlund-Johnell I, Orwoll E, Ohlsson C. 2006. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 21:529–535 [PubMed] [Google Scholar]
53. Lorentzon M, Swanson C, Andersson N, Mellström D, Ohlsson C. 2005. Free testosterone is a positive, whereas free estradiol is a negative, predictor of cortical bone size in young Swedish men: the GOOD study. J Bone Miner Res 20:1334–1341 [PubMed] [Google Scholar]
54. Vasilkova O, Mokhort T, Sanec I, Sharshakova T, Hayashida N, Takamura N. 2011. Testosterone is an independent determinant of bone mineral density in men with type 2 diabetes mellitus. Clin Chem Lab Med 49:99–103 [PubMed] [Google Scholar]
55. Werny DM, Saraiya M, Gregg EW. 2006. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001–2002. Am J Epidemiol 164:978–983 [PubMed] [Google Scholar]
56. Dhindsa S, Upadhyay M, Viswanathan P, Howard S, Chaudhuri A, Dandona P. 2008. Relationship of prostate-specific antigen to age and testosterone in men with type 2 diabetes mellitus. Endocr Pract 14:1000–1005 [PubMed] [Google Scholar]
57. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. 2006. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871–1877 [PubMed] [Google Scholar]
58. Heikkilä R, Aho K, Heliövaara M, Hakama M, Marniemi J, Reunanen A, Knekt P. 1999. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 86:312–315 [PubMed] [Google Scholar]
59. Kapoor D, Goodwin E, Channer KS, Jones TH. 2006. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154:899–906 [PubMed] [Google Scholar]
60. Heufelder AE, Saad F, Bunck MC, Gooren L. 2009. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 30:726–733 [PubMed] [Google Scholar]
61. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS. 2011. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 Study). Diabetes Care 34:828–837 [PMC free article] [PubMed] [Google Scholar]
62. Lee CH, Kuo SW, Hung YJ, Hsieh CH, He CT, Yang TC, Lian WC, Chyi-Fan S, Pei D. 2005. The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. Endocr Res 31:139–148 [PubMed] [Google Scholar]
63. Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R. 2011. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 8:284–293 [PubMed] [Google Scholar]
64. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM. 2010. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95:2560–2575 [PubMed] [Google Scholar]
65. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. 2010. Adverse events associated with testosterone administration. N Engl J Med 363:109–122 [PMC free article] [PubMed] [Google Scholar]
66. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, Wu FC. 2010. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 95:639–650 [PubMed] [Google Scholar]
67. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. 2005. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 90:1502-1510 [PubMed] [Google Scholar]
68. Nair KS, Rizza RA, O'Brien P, Dhatariya K, Short KR, Nehra A, Vittone JL, Klee GG, Basu A, Basu R, Cobelli C, Toffolo G, Dalla Man C, Tindall DJ, Melton LJ, 3rd, Smith GE, Khosla S, Jensen MD. 2006. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 355:1647–1659 [PubMed] [Google Scholar]
69. Muraleedharan V, Marsh H, Jones H, Low testosterone predicts increased mortality and testosterone replacement therapy improves survival in men with type 2 diabetes. Proc Meeting of the British Endocrine Societies/Society for Endocrinology, Birmingham, UK, 2011 (Abstract 25 P163) [Google Scholar]
70. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM. 2009. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 54:919–927 [PubMed] [Google Scholar]
71. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. 2007. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 156:595–602 [PubMed] [Google Scholar]